News

Sep 05, 2023 FOSTER CITY, Calif. & SAN DIEGO–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the completion of Mirum’s previously announced acquisition of Travere’s bile acid product portfolio that includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings (the “Asset Purchase”). In…

Aug 10, 2023 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on August 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 34,200 shares of common stock and 17,100 restricted stock units (“RSUs”) to six new employees under Mirum’s 2020 Inducement…

Aug 03, 2023 – $37.5 million total revenue, including net product sales for LIVMARLI® (maralixibat) oral solution of $32.5 million, for second quarter 2023– Acquiring CHENODAL® and CHOLBAM®, advancing Mirum’s leadership in pediatric hepatology with a multi-product franchise– Four late-stage clinical trial data readouts expected later this year– Conference call to provide business updates today, August 3…

Oct 24, 2023 https://www.curasen.com/wp-content/uploads/2023/10/Poster-034-Harrison-CTAD-2023-FINAL2.pdf

October 9, 2023, San Mateo, CA – CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it has received a strategic investment of up to $5.8 million from the Alzheimer’s Drug Discovery Foundation (ADDF) to advance CST-3056, an alpha-1A adrenoceptor (α1A-AR) agonist for the treatment of Alzheimer’s disease. “We are thrilled…

October 31, 2023 PDF Version BOSTON–(BUSINESS WIRE)–Oct. 31, 2023– Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that updated data from the Phase 2 trial evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC product candidate,…